Source comparison
Best Tesamorelin + Ipamorelin Blend for Enhanced GH Release: Protocol Comparison
Different research objectives require different protocol structures. The table below compares three common approaches, each optimized for specific study parameters. | Protocol Type | Tesamorelin Dose | Ipamorelin Dose | Frequency | Duration | Primary Study Obj
This comparison does not assign a generated winner or score.
- Different research objectives require different protocol structures. The table below compares three common approaches, each optimized for specific study parameters.
- | Protocol Type | Tesamorelin Dose | Ipamorelin Dose | Frequency | Duration | Primary Study Objective | Professional Assessment ||—|—|—|—|—|—|| Standard Daily | 1mg | 200mcg | Once daily before bed | 12-16 weeks | Baseline GH elevation with minimal receptor adaptation. Suitable for initial feasibility studies | Most consistent data across published research; best starting point for novel investigations || High-Intensity | 2mg | 300mcg | Once daily before bed | 8-12 weeks | Maximal GH stimulation over shorter study windows. Used when rapid outcome measurement is required | Produces highest peak GH levels but increases risk of receptor desensitization; requires planned washout || Pulsed Maintenance | 1mg | 200mcg | 5 days on / 2 days off | 16-24 weeks | Extended study duration with maintained receptor sensitivity. Used for long-term metabolic research | Lower peak GH than daily protocols but superior sustained response beyond week 12; prevents adaptation |
- The Standard Daily protocol appears most frequently in peer-reviewed studies for good reason. It balances efficacy with sustainability. The 1mg tesamorelin / 200mcg ipamorelin combination produces mean GH elevations of 4.2-5.8 fold over baseline in the first 8 weeks, with measurable IGF-1 increases (typically 40-70 ng/mL above baseline) appearing within 2-4 weeks. This protocol works well for body composition studies where the primary endpoints are visceral fat reduction and lean mass changes over 12-16 week observation windows.
- High-Intensity protocols using 2mg tesamorelin push closer to the physiological ceiling of GH secretion. Published studies show peak GH concentrations reaching 12-18 ng/mL within 90 minutes of administration. Roughly double the response of standard dosing. The tradeoff is adaptation. GHRH receptor density begins declining measurably around week 6-8 at this dose level, which is why these protocols rarely extend beyond 12 weeks. This approach makes sense when research design requires rapid, pronounced effects. Such as acute metabolic studies or when outcomes must be measured within compressed timelines.
- Pulsed Maintenance protocols introduce planned washout days to prevent receptor downregulation. The 5-on/2-off schedule allows GHRH and GHS-R1a receptor expression to recover during the 48-hour break, restoring sensitivity for the next administration cycle. This protocol shows lower average GH levels week-to-week compared to daily dosing, but crucially, it maintains consistent response through week 20 and beyond. The point where daily protocols have typically plateaued or required dose escalation. We recommend this approach for any study design extending past 16 weeks.